

Starting dose of ultraviolet B to treat psoriasis

Submission date 03/12/2009	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 10/12/2009	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 10/11/2010	Condition category Skin and Connective Tissue Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Robert Dawe

Contact details

Photobiology Unit, Department of Dermatology
Ninewells Hospital and Medical School
Dundee
United Kingdom
DD1 9SY

Additional identifiers

Protocol serial number

NRR N0405128578

Study information

Scientific Title

A randomised comparison of methods of selecting narrow-band ultraviolet B starting dose to treat chronic psoriasis

Study objectives

Does the method of selecting narrowband ultraviolet B (NB-UVB) starting dose, whether based upon individual patient minimal erythral dose (50% or 70%) or not, alter efficacy or adverse effects of narrowband ultraviolet B phototherapy to treat chronic psoriasis?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Tayside local regional ethics committee (LREC) approved in 2003 (ref: 109/03)

Study design

Randomised 3-arm triple blind parallel group trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Psoriasis; dermatological disease

Interventions

Narrowband ultraviolet B phototherapy: administered as routine except for decision on start dose. The method of deciding first narrowband ultraviolet B dose was randomised:

1. Start dose 70% minimal erythema dose
2. Start dose 50% minimal erythema dose
3. Start dose skin phototype based

Treatments were administered 3-times weekly. Duration of treatment and study follow-up was until clearance or minimal residual activity (MRA). The total number of treatments varied (all groups median 27 treatments, maximum 61 treatments) and duration of attending for treatment was median 10 weeks (maximum 34 weeks). The apparent discrepancy (e.g. 34 weeks corresponding to 61 treatments) is because not all patients always attended every week 3-times per week).

There was no study follow up phase after completion of treatment course many patients have been followed up longer, but not as part of this study.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

1. Number of narrowband ultraviolet B treatments to clearance of psoriasis
2. Number of important (uncomfortable or painful) erythema episodes occurring during treatment courses

Key secondary outcome(s)

1. Change in Psoriasis Disability Index (Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of Sickness Impact Profile and Psoriasis Disability Index in Psoriasis. Br J Dermatol. Dec 1990;123(6): 751-756.)
2. Change in Psoriasis Area and Severity Index

Both outcomes above were measured at baseline before the first UVB treatment, the 15th and the last treatment visit.

Completion date

15/10/2007

Eligibility

Key inclusion criteria

All patients referred for NB-UVB phototherapy for chronic (defined as present for more than one year) psoriasis (as diagnosed by a dermatologist), from our catchment area

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Less than 16 years old
2. On systemic immunosuppressant therapy or retinoids within the preceding three months

Date of first enrolment

15/12/2003

Date of final enrolment

15/10/2007

Locations

Countries of recruitment

United Kingdom

Scotland

Study participating centre

Photobiology Unit, Department of Dermatology

Dundee

United Kingdom

DD1 9SY

Sponsor information

Organisation

NHS Tayside (UK)

ROR

<https://ror.org/000ywep40>

Funder(s)

Funder type

Other

Funder Name

NHS Tayside (UK) - Photobiology Unit Charitable Trust

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/02/2011		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes